Inhibition of EGFR, HER2, and HER3 Signalling in Patients With Colorectal Cancer Wild-Type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): A Phase 2–3 Randomised Trial
Lancet Gastroenterology and Hepatology, The - United Kingdom
doi 10.1016/s2468-1253(17)30394-1
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2018
Authors
Publisher
Elsevier BV